The document summarizes emerging concepts around SGLT2 inhibitors and renal outcomes. It discusses the mechanism of action of SGLT2 inhibitors including reducing glucose reabsorption and increasing sodium delivery to the macula densa. A key trial on the SGLT2 inhibitor dapagliflozin showed it reduced the composite of sustained ≥50% eGFR decline, end-stage kidney disease, or renal or cardiovascular death by 39% compared to placebo in patients with chronic kidney disease. Updated guidelines now recommend SGLT2 inhibitors to reduce renal and cardiovascular risk in patients with chronic kidney disease based on these renal protection benefits shown in clinical trials.
The EMPA-KIDNEY trial aims to evaluate whether empagliflozin can benefit patients with chronic kidney disease (CKD) and cardiovascular disease outcomes in patients with or without diabetes. The trial plans to enroll approximately 6,000 patients with CKD at risk of kidney disease progression, defined as an eGFR of 20-45 mL/min/1.73 m2 or an eGFR of 45-90 mL/min/1.73 m2 with albuminuria above 200 mg/g. Patients will be randomly assigned to receive empagliflozin 10 mg daily or placebo daily in addition to standard of care. The primary outcome is a composite of cardiovascular death, end-stage kidney disease,
This document discusses glucose-lowering therapies and the clinical place of SGLT2 inhibitor agents. It presents the case of a 52-year-old male patient with type 2 diabetes, hypertension, and coronary artery disease. It analyzes adding empagliflozin or sitagliptin to the patient's current metformin regimen and reviews long-term trial data showing empagliflozin's superior effects on HbA1c reduction, weight loss, and hypoglycemia risk reduction compared to glimepiride. The document also discusses empagliflozin's benefits on blood pressure and potential cardioprotective mechanisms of action beyond glycemic control such as reducing cardiac fibrosis. It emphasizes the importance of individual
SGLT2I The paradigm change in diabetes managementPraveen Nagula
Just like ARNI, SGLT2I have changed the face of diabetes management and they have a good profile in multimodality management because of pleiotropic effects
A 52-year-old man with type 2 diabetes of 8 years was uncontrolled on insulin therapy and gaining weight. He was obese, had hypertension and dyslipidemia. Dapagliflozin was added to his insulin regimen while reducing his insulin dose by 25%. This led to reductions in his HbA1c, weight, blood pressure, and lipid levels over 6 months of follow up while preventing further increases to his insulin needs. Dapagliflozin provided glycemic control and weight loss without increasing hypoglycemia risk for this patient with multiple comorbidities.
SGLT2 inhibitors lower blood glucose by reducing glucose reabsorption in the kidney. Three SGLT2 inhibitors have been approved by the FDA to treat type 2 diabetes: canagliflozin, dapagliflozin, and empagliflozin. They have similar mechanisms of action and efficacy outcomes, lowering A1c by 0.5-1% and fasting plasma glucose by 15-40 mg/dL on average. Side effects include increased urinary tract and genital infections as well as volume depletion related side effects. SGLT2 inhibitors provide an additional treatment option for type 2 diabetes through their insulin-independent mechanism of action.
Silvio E. Inzucchi, MD, prepared useful Practice Aids pertaining to type 2 diabetes management for this CME activity titled "The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Considerations." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2l4h3Ss. CME credit will be available until June 27, 2019.
This document discusses sodium glucose cotransporter-2 inhibitors (SGLT2i) across the spectrum of renal diseases. It begins with an overview of renal glucose handling and the role of the SGLT2 channel. It then reviews the rationale for SGLT2 inhibition in diabetic and non-diabetic kidney diseases and basic SGLT2i pharmacology. Finally, it examines clinical outcomes data from trials demonstrating the cardiovascular, renal, and heart failure benefits of SGLT2is across levels of renal function and in diabetic and non-diabetic patients.
The EMPA-KIDNEY trial aims to evaluate whether empagliflozin can benefit patients with chronic kidney disease (CKD) and cardiovascular disease outcomes in patients with or without diabetes. The trial plans to enroll approximately 6,000 patients with CKD at risk of kidney disease progression, defined as an eGFR of 20-45 mL/min/1.73 m2 or an eGFR of 45-90 mL/min/1.73 m2 with albuminuria above 200 mg/g. Patients will be randomly assigned to receive empagliflozin 10 mg daily or placebo daily in addition to standard of care. The primary outcome is a composite of cardiovascular death, end-stage kidney disease,
This document discusses glucose-lowering therapies and the clinical place of SGLT2 inhibitor agents. It presents the case of a 52-year-old male patient with type 2 diabetes, hypertension, and coronary artery disease. It analyzes adding empagliflozin or sitagliptin to the patient's current metformin regimen and reviews long-term trial data showing empagliflozin's superior effects on HbA1c reduction, weight loss, and hypoglycemia risk reduction compared to glimepiride. The document also discusses empagliflozin's benefits on blood pressure and potential cardioprotective mechanisms of action beyond glycemic control such as reducing cardiac fibrosis. It emphasizes the importance of individual
SGLT2I The paradigm change in diabetes managementPraveen Nagula
Just like ARNI, SGLT2I have changed the face of diabetes management and they have a good profile in multimodality management because of pleiotropic effects
A 52-year-old man with type 2 diabetes of 8 years was uncontrolled on insulin therapy and gaining weight. He was obese, had hypertension and dyslipidemia. Dapagliflozin was added to his insulin regimen while reducing his insulin dose by 25%. This led to reductions in his HbA1c, weight, blood pressure, and lipid levels over 6 months of follow up while preventing further increases to his insulin needs. Dapagliflozin provided glycemic control and weight loss without increasing hypoglycemia risk for this patient with multiple comorbidities.
SGLT2 inhibitors lower blood glucose by reducing glucose reabsorption in the kidney. Three SGLT2 inhibitors have been approved by the FDA to treat type 2 diabetes: canagliflozin, dapagliflozin, and empagliflozin. They have similar mechanisms of action and efficacy outcomes, lowering A1c by 0.5-1% and fasting plasma glucose by 15-40 mg/dL on average. Side effects include increased urinary tract and genital infections as well as volume depletion related side effects. SGLT2 inhibitors provide an additional treatment option for type 2 diabetes through their insulin-independent mechanism of action.
Silvio E. Inzucchi, MD, prepared useful Practice Aids pertaining to type 2 diabetes management for this CME activity titled "The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Considerations." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2l4h3Ss. CME credit will be available until June 27, 2019.
This document discusses sodium glucose cotransporter-2 inhibitors (SGLT2i) across the spectrum of renal diseases. It begins with an overview of renal glucose handling and the role of the SGLT2 channel. It then reviews the rationale for SGLT2 inhibition in diabetic and non-diabetic kidney diseases and basic SGLT2i pharmacology. Finally, it examines clinical outcomes data from trials demonstrating the cardiovascular, renal, and heart failure benefits of SGLT2is across levels of renal function and in diabetic and non-diabetic patients.
Effects of Sodium Glucose contransporter (SGLT2) inhibition on renal outcomes in patients with (diabetic) chronic kidney disease.
Presentation given during the East by Southwest, Annual Update in Nephrology, September 17th 2017, Santa Fe, NM
http://medicine.unm.edu/academic-divisions/nephrology/east-by-southwest.html
SGLT-2 inhibitors lower blood glucose levels by reducing renal glucose reabsorption and increasing glucose excretion in the urine. Empagliflozin is a selective SGLT-2 inhibitor that lowers both fasting and post-prandial plasma glucose levels. In clinical trials, empagliflozin led to an HbA1c reduction of over 1% compared to placebo when used as both monotherapy and add-on therapy to other glucose-lowering medications. Empagliflozin was also associated with weight loss, reduced blood pressure, and a lower risk of hypoglycemia compared to sulfonylurea therapy.
Empagliflozin and Cardiovascular OutcomesUyen Nguyen
1) The EMPA-REG OUTCOME trial evaluated the cardiovascular outcomes of empagliflozin compared to placebo in over 7000 patients with type 2 diabetes at high risk of cardiovascular events.
2) Empagliflozin was found to significantly reduce the risk of the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke compared to placebo.
3) Additional benefits observed with empagliflozin included a significant reduction in all-cause mortality, cardiovascular mortality, and hospitalization for heart failure.
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/kanEHVsStsI
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
This document summarizes the history and mechanisms of action of SGLT2 inhibitors, a class of diabetes medications. Key points include:
- SGLT2 inhibitors work by blocking glucose reabsorption in the kidney, inducing glucosuria and lowering blood glucose levels.
- Several large clinical trials demonstrated SGLT2 inhibitors effectively lower HbA1c and blood glucose with a low risk of hypoglycemia compared to other diabetes medications.
- Beyond glycemic control, SGLT2 inhibitors provide additional benefits like weight loss, blood pressure reduction, and improved cardiac outcomes.
Javed Butler, MD, MPH, MBA, discusses heart failure in this CME activity titled, "New Frontiers in Managing Heart Failure: Are SGLT2 Inhibitors the Next Leap Forward in Optimizing Patient Care?" For the full presentation, downloadable infographics, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2JG2v9l. CME credit will be available until May 29, 2020.
The CREDENCE trial evaluated the effect of canagliflozin vs placebo on renal outcomes in patients with type 2 diabetes and chronic kidney disease. Over 2.6 years of follow up:
1) Canagliflozin reduced the composite outcome of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death by 30% compared to placebo.
2) Canagliflozin also reduced cardiovascular death, myocardial infarction, stroke or hospitalization for heart failure by 30% compared to placebo.
3) The trial demonstrated that canagliflozin provided renoprotective and cardiovascular benefits in patients with type 2 diabetes and chronic kidney disease.
Presentation given to our fellowship program about diabetic kidney disease.
2022 update discussing SGLT2i, MRA (e.g. finerenone), health economics and beyond
1. The diabtologist wished for an oral hypoglycemic agent that controls blood glucose without hypoglycemia.
2. He wished for it to be used as a first line drug or added to other commonly used drugs like metformin or insulin.
3. He wished for it to have significant cardiovascular benefits and minimal side effects.
4. The genie granted these wishes by presenting dapagliflozin, an SGLT2 inhibitor that meets all the criteria wished for.
This document discusses SGLT2 inhibitors and DPP-4 inhibitors for the treatment of type 2 diabetes. SGLT2 inhibitors work by increasing glucose excretion in the urine, independently of insulin. They modestly lower blood pressure and weight. DPP-4 inhibitors work by inhibiting the DPP-4 enzyme and increasing GLP-1 and GIP levels. Both classes have few hypoglycemia risks but SGLT2 inhibitors should be used with caution in those with kidney impairment. Empagliflozin and canagliflozin are recommended for patients with cardiovascular disease.
EMPA-REG: un punto de inflexión en el tratamiento de la diabetes
18/11/15 20:00h Casa del Corazón (Madrid)
http://empareg.secardiologia.es
#EMPAREG
Resultados del estudio EMPA-REG
Dr. Domingo Marzal Martín, Complejo Hospitalario de Mérida (Badajoz)
@domingomarzal
This document discusses the use of SGLT2 inhibitors (SGLT2i) in managing diabetes. It presents three case studies of patients with diabetes and cardiovascular complications who may benefit from SGLT2i treatment. It summarizes clinical trial data showing that empagliflozin lowers HbA1c, fasting plasma glucose, body weight, and blood pressure compared to other antidiabetic drugs. Empagliflozin also reduces visceral and subcutaneous fat. The document concludes that SGLT2i like empagliflozin provide glycemic control and cardiovascular benefits and can be considered as an addition to metformin for treating diabetes.
This document discusses diabetic kidney disease (DKD). It provides information on the epidemiology, clinical presentation, pathogenesis, standard of care, and pharmacological interventions to reduce cardiorenal risk in patients with type 2 diabetes. Regarding standard of care, it outlines glycemic and blood pressure targets, the use of RAAS inhibitors and statins, and glucose-lowering medications. It then discusses how SGLT2 inhibitors have shown benefits in reducing cardiovascular, renal, and heart failure outcomes as well as slowing kidney disease progression in patients with DKD and type 2 diabetes.
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that enhances glucose-dependent insulin secretion from pancreatic beta cells. GLP-1 levels are reduced in patients with type 2 diabetes. Therapeutic strategies that augment the GLP-1 pathway include GLP-1 receptor agonists such as exenatide and liraglutide, as well as dipeptidyl peptidase-4 (DPP-4) inhibitors which prevent the breakdown of endogenous GLP-1. These incretin-based therapies lower blood glucose levels with a low risk of hypoglycemia and promote weight loss, offering an important treatment option for patients with type 2 diabetes.
Sglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic controlDrSuman Roy
This document discusses the cardiovascular and renal benefits of SGLT2 inhibitors (SGLT2i), a class of antidiabetic drugs. It summarizes data from clinical trials showing that SGLT2i like empagliflozin, canagliflozin, and dapagliflozin lower the risks of cardiovascular death, heart failure hospitalization, and progression of kidney disease in patients with type 2 diabetes. However, it also notes potential adverse effects of SGLT2i including genitourinary infections, hypotension, acute kidney injury, bone fractures, diabetic ketoacidosis, and amputations. The document concludes that SGLT2i provide risk-benefit for patients with type
The document discusses a secondary analysis of the FIDELIO-DKD trial presented by Gerasimos Filippatos at the Heart Failure 2021 conference. The analysis looked at the effects of finerenone in patients with chronic kidney disease and type 2 diabetes, who either did or did not have a history of heart failure. Of the over 5,700 patients in the main FIDELIO-DKD trial, 436 (7.7%) had a history of heart failure at baseline. The secondary analysis examined cardiovascular outcomes including cardiovascular death, non-fatal heart attack or stroke, and hospitalization for heart failure.
The FIGARO-DKD trial found that:
1) Finerenone significantly reduced the risk of the primary cardiovascular outcome (composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) by 13% compared to placebo in patients with chronic kidney disease and type 2 diabetes.
2) The cardiovascular benefit was primarily driven by a reduction in hospitalization for heart failure despite excluding patients with symptomatic heart failure with reduced ejection fraction.
3) Finerenone did not significantly reduce the risk of a sustained 40% decline in eGFR but did trend toward improving the clinically accepted outcome of a sustained 57% decline in eGFR compared to placebo.
SGLT-2 inhibitors have shown promising cardiovascular and renal benefits:
1) Trials have found SGLT-2 inhibitors reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, as well as reducing heart failure hospitalizations in those with diabetes and cardiovascular risk factors.
2) Studies also show SGLT-2 inhibitors improve outcomes for patients with heart failure with reduced ejection fraction, reducing rates of heart failure hospitalization and mortality regardless of diabetes status or background heart failure therapies.
3) SGLT-2 inhibitors were also found to reduce the risk of renal death or progression to end-stage kidney disease in patients with type 2 diabetes and macroalbuminuria.
- The document discusses the burden of diabetic kidney disease and the benefits of SGLT2 inhibitors (SGLT2i).
- It notes that progression of diabetic kidney disease depends on glomerular blood pressure and that SGLT2i lower intraglomerular pressure through their mechanisms of action.
- Clinical trials show that SGLT2i provide renal benefits including postponing end-stage renal disease and that earlier treatment provides longer-term protection of kidney function.
SGLT2 Inhibitor therapy has opened up an exciting avenue for the Physicians to manage the patients with CKD . The slide set highlights the major trials on the drug showing remarkable benefits.
Effects of Sodium Glucose contransporter (SGLT2) inhibition on renal outcomes in patients with (diabetic) chronic kidney disease.
Presentation given during the East by Southwest, Annual Update in Nephrology, September 17th 2017, Santa Fe, NM
http://medicine.unm.edu/academic-divisions/nephrology/east-by-southwest.html
SGLT-2 inhibitors lower blood glucose levels by reducing renal glucose reabsorption and increasing glucose excretion in the urine. Empagliflozin is a selective SGLT-2 inhibitor that lowers both fasting and post-prandial plasma glucose levels. In clinical trials, empagliflozin led to an HbA1c reduction of over 1% compared to placebo when used as both monotherapy and add-on therapy to other glucose-lowering medications. Empagliflozin was also associated with weight loss, reduced blood pressure, and a lower risk of hypoglycemia compared to sulfonylurea therapy.
Empagliflozin and Cardiovascular OutcomesUyen Nguyen
1) The EMPA-REG OUTCOME trial evaluated the cardiovascular outcomes of empagliflozin compared to placebo in over 7000 patients with type 2 diabetes at high risk of cardiovascular events.
2) Empagliflozin was found to significantly reduce the risk of the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke compared to placebo.
3) Additional benefits observed with empagliflozin included a significant reduction in all-cause mortality, cardiovascular mortality, and hospitalization for heart failure.
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/kanEHVsStsI
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
This document summarizes the history and mechanisms of action of SGLT2 inhibitors, a class of diabetes medications. Key points include:
- SGLT2 inhibitors work by blocking glucose reabsorption in the kidney, inducing glucosuria and lowering blood glucose levels.
- Several large clinical trials demonstrated SGLT2 inhibitors effectively lower HbA1c and blood glucose with a low risk of hypoglycemia compared to other diabetes medications.
- Beyond glycemic control, SGLT2 inhibitors provide additional benefits like weight loss, blood pressure reduction, and improved cardiac outcomes.
Javed Butler, MD, MPH, MBA, discusses heart failure in this CME activity titled, "New Frontiers in Managing Heart Failure: Are SGLT2 Inhibitors the Next Leap Forward in Optimizing Patient Care?" For the full presentation, downloadable infographics, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2JG2v9l. CME credit will be available until May 29, 2020.
The CREDENCE trial evaluated the effect of canagliflozin vs placebo on renal outcomes in patients with type 2 diabetes and chronic kidney disease. Over 2.6 years of follow up:
1) Canagliflozin reduced the composite outcome of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death by 30% compared to placebo.
2) Canagliflozin also reduced cardiovascular death, myocardial infarction, stroke or hospitalization for heart failure by 30% compared to placebo.
3) The trial demonstrated that canagliflozin provided renoprotective and cardiovascular benefits in patients with type 2 diabetes and chronic kidney disease.
Presentation given to our fellowship program about diabetic kidney disease.
2022 update discussing SGLT2i, MRA (e.g. finerenone), health economics and beyond
1. The diabtologist wished for an oral hypoglycemic agent that controls blood glucose without hypoglycemia.
2. He wished for it to be used as a first line drug or added to other commonly used drugs like metformin or insulin.
3. He wished for it to have significant cardiovascular benefits and minimal side effects.
4. The genie granted these wishes by presenting dapagliflozin, an SGLT2 inhibitor that meets all the criteria wished for.
This document discusses SGLT2 inhibitors and DPP-4 inhibitors for the treatment of type 2 diabetes. SGLT2 inhibitors work by increasing glucose excretion in the urine, independently of insulin. They modestly lower blood pressure and weight. DPP-4 inhibitors work by inhibiting the DPP-4 enzyme and increasing GLP-1 and GIP levels. Both classes have few hypoglycemia risks but SGLT2 inhibitors should be used with caution in those with kidney impairment. Empagliflozin and canagliflozin are recommended for patients with cardiovascular disease.
EMPA-REG: un punto de inflexión en el tratamiento de la diabetes
18/11/15 20:00h Casa del Corazón (Madrid)
http://empareg.secardiologia.es
#EMPAREG
Resultados del estudio EMPA-REG
Dr. Domingo Marzal Martín, Complejo Hospitalario de Mérida (Badajoz)
@domingomarzal
This document discusses the use of SGLT2 inhibitors (SGLT2i) in managing diabetes. It presents three case studies of patients with diabetes and cardiovascular complications who may benefit from SGLT2i treatment. It summarizes clinical trial data showing that empagliflozin lowers HbA1c, fasting plasma glucose, body weight, and blood pressure compared to other antidiabetic drugs. Empagliflozin also reduces visceral and subcutaneous fat. The document concludes that SGLT2i like empagliflozin provide glycemic control and cardiovascular benefits and can be considered as an addition to metformin for treating diabetes.
This document discusses diabetic kidney disease (DKD). It provides information on the epidemiology, clinical presentation, pathogenesis, standard of care, and pharmacological interventions to reduce cardiorenal risk in patients with type 2 diabetes. Regarding standard of care, it outlines glycemic and blood pressure targets, the use of RAAS inhibitors and statins, and glucose-lowering medications. It then discusses how SGLT2 inhibitors have shown benefits in reducing cardiovascular, renal, and heart failure outcomes as well as slowing kidney disease progression in patients with DKD and type 2 diabetes.
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that enhances glucose-dependent insulin secretion from pancreatic beta cells. GLP-1 levels are reduced in patients with type 2 diabetes. Therapeutic strategies that augment the GLP-1 pathway include GLP-1 receptor agonists such as exenatide and liraglutide, as well as dipeptidyl peptidase-4 (DPP-4) inhibitors which prevent the breakdown of endogenous GLP-1. These incretin-based therapies lower blood glucose levels with a low risk of hypoglycemia and promote weight loss, offering an important treatment option for patients with type 2 diabetes.
Sglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic controlDrSuman Roy
This document discusses the cardiovascular and renal benefits of SGLT2 inhibitors (SGLT2i), a class of antidiabetic drugs. It summarizes data from clinical trials showing that SGLT2i like empagliflozin, canagliflozin, and dapagliflozin lower the risks of cardiovascular death, heart failure hospitalization, and progression of kidney disease in patients with type 2 diabetes. However, it also notes potential adverse effects of SGLT2i including genitourinary infections, hypotension, acute kidney injury, bone fractures, diabetic ketoacidosis, and amputations. The document concludes that SGLT2i provide risk-benefit for patients with type
The document discusses a secondary analysis of the FIDELIO-DKD trial presented by Gerasimos Filippatos at the Heart Failure 2021 conference. The analysis looked at the effects of finerenone in patients with chronic kidney disease and type 2 diabetes, who either did or did not have a history of heart failure. Of the over 5,700 patients in the main FIDELIO-DKD trial, 436 (7.7%) had a history of heart failure at baseline. The secondary analysis examined cardiovascular outcomes including cardiovascular death, non-fatal heart attack or stroke, and hospitalization for heart failure.
The FIGARO-DKD trial found that:
1) Finerenone significantly reduced the risk of the primary cardiovascular outcome (composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) by 13% compared to placebo in patients with chronic kidney disease and type 2 diabetes.
2) The cardiovascular benefit was primarily driven by a reduction in hospitalization for heart failure despite excluding patients with symptomatic heart failure with reduced ejection fraction.
3) Finerenone did not significantly reduce the risk of a sustained 40% decline in eGFR but did trend toward improving the clinically accepted outcome of a sustained 57% decline in eGFR compared to placebo.
SGLT-2 inhibitors have shown promising cardiovascular and renal benefits:
1) Trials have found SGLT-2 inhibitors reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, as well as reducing heart failure hospitalizations in those with diabetes and cardiovascular risk factors.
2) Studies also show SGLT-2 inhibitors improve outcomes for patients with heart failure with reduced ejection fraction, reducing rates of heart failure hospitalization and mortality regardless of diabetes status or background heart failure therapies.
3) SGLT-2 inhibitors were also found to reduce the risk of renal death or progression to end-stage kidney disease in patients with type 2 diabetes and macroalbuminuria.
- The document discusses the burden of diabetic kidney disease and the benefits of SGLT2 inhibitors (SGLT2i).
- It notes that progression of diabetic kidney disease depends on glomerular blood pressure and that SGLT2i lower intraglomerular pressure through their mechanisms of action.
- Clinical trials show that SGLT2i provide renal benefits including postponing end-stage renal disease and that earlier treatment provides longer-term protection of kidney function.
SGLT2 Inhibitor therapy has opened up an exciting avenue for the Physicians to manage the patients with CKD . The slide set highlights the major trials on the drug showing remarkable benefits.
Three cases of acute myocardial infarction are presented. All three patients had type 2 diabetes and other cardiovascular risk factors like hypertension and dyslipidemia. They presented with chest pain and ST-segment changes on electrocardiogram. All underwent emergency cardiac catheterization and had stents placed in obstructed coronary arteries. Strict control of blood sugar, blood pressure, and lipids is emphasized going forward to prevent further cardiovascular complications. The role of SGLT2 inhibitors in cardiovascular and renal protection for patients with diabetes is also discussed.
This document discusses the clinical profile and efficacy of the combination drug GLYXAMBI, which contains empagliflozin and linagliptin. It summarizes clinical trial results showing that GLYXAMBI provides significant reductions in HbA1c and body weight compared to the individual components alone in patients with type 2 diabetes. Guidelines from major diabetes organizations have been updated to recommend SGLT2 inhibitors like empagliflozin and GLP-1 receptor agonists to reduce cardiovascular risk based on positive cardiovascular outcomes trial results.
Cardiometabolic Benefits of Renal Diabetes and Obesity MedicationsChristos Argyropoulos
1. This document summarizes a presentation on pharmacological interventions to reduce cardiorenal risk in patients with diabetes mellitus type 2 (DM2) and chronic kidney disease (CKD).
2. It discusses using urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) to diagnose diabetic kidney disease (DKD) and stratify cardiovascular risk.
3. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were shown to reduce cardiovascular, renal, and heart failure outcomes, while mineralocorticoid receptor antagonists (MRAs) like finerenone improved proteinuria and cardiorenal outcomes.
This document provides an overview of canagliflozin, an SGLT2 inhibitor used to treat type 2 diabetes. It discusses the pathogenesis of type 2 diabetes, progressive beta cell dysfunction, and the kidney's role in glucose regulation. It then reviews canagliflozin's mechanism of action as an SGLT2 inhibitor, increasing urinary glucose excretion and reducing blood glucose levels. The document summarizes canagliflozin's clinical trials, pharmacokinetics, efficacy, safety profile, and effects on renal function and lipids.
This document discusses aldosterone and mineralocorticoid receptor antagonism (MRA) in diabetes and chronic kidney disease (CKD). It provides an overview of aldosterone's role in inflammation and fibrosis in cardiovascular and kidney diseases. It outlines the pharmacology of MRAs like finerenone and their clinical outcomes in reducing kidney failure, cardiovascular events, and hospitalizations in diabetic kidney disease based on trials like FIDELIO-CKD and FIGARO-DKD. It also addresses managing the risk of hyperkalemia with MRAs and the potential role of combination MRA/SGLT2 inhibitor therapy in CKD.
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...rdaragnez
This document summarizes research on diabetes treatment and outcomes from several long-term clinical trials. It finds that intensive glucose control early in type 2 diabetes can significantly reduce cardiovascular and renal complications long-term. However, rapidly lowering glucose in those with existing cardiovascular disease may increase mortality risk. Multifactorial treatment including blood pressure and glucose control provides substantial benefits and is recommended for all type 2 diabetes patients.
1) The document discusses the double burden of diabetes and chronic kidney disease (CKD) in India. Over 50% of patients with type 2 diabetes in one study had CKD as defined by reduced eGFR or albuminuria.
2) Microalbuminuria is an early marker of kidney dysfunction in patients with diabetes. Higher levels of microalbuminuria are associated with poorer glycemic control and longer duration of diabetes.
3) The CARMELINA trial evaluated the cardiovascular and kidney safety of linagliptin versus placebo in patients with type 2 diabetes at high cardiovascular risk but relatively early in their disease. Linagliptin demonstrated kidney safety and reduced the risk of microvascular outcomes.
This document summarizes the key details of the DAPA-CKD clinical trial which assessed the effects of the SGLT2 inhibitor dapagliflozin in patients with chronic kidney disease (CKD). The trial randomized over 4,000 patients with CKD stages 2-4 and elevated urinary albumin levels to receive either dapagliflozin 10mg daily or placebo. The primary outcome was a composite of sustained decline in kidney function, need for kidney replacement therapy, or death from renal or cardiovascular causes. Secondary outcomes included safety events. The trial found that dapagliflozin reduced the primary composite outcome compared to placebo in patients with CKD with and without diabetes.
Slidedeck of the presentation I gave during the East by Southwest conference, co-organized by the Division of Nephrology (UNM) and the Renal and Electrolyte Division (UPMC)
SGLT 2 inhibitors Empagliflozin in Diabetes MellitusGovindRankawat1
Two sodium glucose transporters, cause glucose reabsorption: SGLT-1 and SGLT-2.
SGLT-2 is found in the proximal tubule of the kidney, accounts for 90% of the re-absorption of glucose.
SGLT-1 is found in the gut and other tissues, account for glucose absorption
On top of glycaemic lowering, SGLT2 inhibitors demonstrates additional clinical benefits versus placebo:
Blood pressure lowering
Weight loss
Reduction in major cardiovascular events in patients with established cardiovascular disease1
The mechanisms responsible for the cardiovascular effects are currently unknown
May be a combination of natriuresis, glycosuria (dual inhibition) and/or Na+/H+ exchange
Ongoing mechanistic studies may provide answers
A study published by Elsevier suggest that after 52 weeks of follow-up empagliflozin and dapagliflozin both groups showed significant reductions in HbA1c and FPG, but the reduction was greater in the empagliflozin group (P < 0.001). Hence, empagliflozin was more effective in reducing HbA1c and improving other cardiometabolic parameters than dapagliflozin
Our aim is to reduce morbidity and mortality related to Non communicable diseases such as hypertension, diabetes, cardiovascular disease, stroke, Obesity, Cancer and lifestyle diseases among those least able to withstand the burden of the disease.
How to link glucose control to cv outcomesYichi Chen
Outline
1.CV risk of DM patient
2.Glucose to CV outcome - Intensive control vs Conventional control
3.Hypoglycemia
4.Different drugs, different outcomes
5.Expect to Future
This document discusses antiplatelet treatment strategies in diabetic patients with acute coronary syndrome (ACS). It summarizes several clinical trials comparing different P2Y12 inhibitors in this population. The key points are:
1. Diabetic patients with ACS have higher mortality and morbidity than non-diabetic patients. Clopidogrel response is more variable in diabetics, with higher rates of non-response.
2. A head-to-head trial found ticagrelor reduced platelet reactivity more than prasugrel in diabetic ACS patients after loading doses, with fewer patients having high on-treatment platelet reactivity.
3. Clinical trials showed ticagrelor and prasug
- Early initiation of high-intensity statin therapy in acute coronary syndrome patients significantly reduces mortality and morbidity rates compared to later initiation or lower-intensity statins. Clinical trials found a 16-36% reduction in major coronary events with early high-dose statin use.
- Guidelines recommend high-intensity statins like atorvastatin 80mg or simvastatin 80mg for acute coronary syndrome patients, though risks like side effects must be considered. Long-term statin therapy is also generally advised after acute coronary syndrome.
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Physiology and chemistry of skin and pigmentation, hairs, scalp, lips and nail, Cleansing cream, Lotions, Face powders, Face packs, Lipsticks, Bath products, soaps and baby product,
Preparation and standardization of the following : Tonic, Bleaches, Dentifrices and Mouth washes & Tooth Pastes, Cosmetics for Nails.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...PECB
Denis is a dynamic and results-driven Chief Information Officer (CIO) with a distinguished career spanning information systems analysis and technical project management. With a proven track record of spearheading the design and delivery of cutting-edge Information Management solutions, he has consistently elevated business operations, streamlined reporting functions, and maximized process efficiency.
Certified as an ISO/IEC 27001: Information Security Management Systems (ISMS) Lead Implementer, Data Protection Officer, and Cyber Risks Analyst, Denis brings a heightened focus on data security, privacy, and cyber resilience to every endeavor.
His expertise extends across a diverse spectrum of reporting, database, and web development applications, underpinned by an exceptional grasp of data storage and virtualization technologies. His proficiency in application testing, database administration, and data cleansing ensures seamless execution of complex projects.
What sets Denis apart is his comprehensive understanding of Business and Systems Analysis technologies, honed through involvement in all phases of the Software Development Lifecycle (SDLC). From meticulous requirements gathering to precise analysis, innovative design, rigorous development, thorough testing, and successful implementation, he has consistently delivered exceptional results.
Throughout his career, he has taken on multifaceted roles, from leading technical project management teams to owning solutions that drive operational excellence. His conscientious and proactive approach is unwavering, whether he is working independently or collaboratively within a team. His ability to connect with colleagues on a personal level underscores his commitment to fostering a harmonious and productive workplace environment.
Date: May 29, 2024
Tags: Information Security, ISO/IEC 27001, ISO/IEC 42001, Artificial Intelligence, GDPR
-------------------------------------------------------------------------------
Find out more about ISO training and certification services
Training: ISO/IEC 27001 Information Security Management System - EN | PECB
ISO/IEC 42001 Artificial Intelligence Management System - EN | PECB
General Data Protection Regulation (GDPR) - Training Courses - EN | PECB
Webinars: https://pecb.com/webinars
Article: https://pecb.com/article
-------------------------------------------------------------------------------
For more information about PECB:
Website: https://pecb.com/
LinkedIn: https://www.linkedin.com/company/pecb/
Facebook: https://www.facebook.com/PECBInternational/
Slideshare: http://www.slideshare.net/PECBCERTIFICATION
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
Introduction to AI for Nonprofits with Tapp Network
10447966.pdf
1. EMERGING CONCEPTS OF SGLT2
INHIBITORS IN RENAL OUTCOMES
Peerapat Thanapongsatorn, MD
Critical Care Nephrologist
Central Chest Institute of Thailand
27th Oct 2022
2. DISCLOSURE
This presentation is supported by AstraZeneca.
I have no conflicts of interest relative to this presentation.
3. OUTLINE
Mechanism of SGLT2 inhibitor with renal protection
Landmark trial of Dapagliflozin on renal outcomes
Updated guideline on SGLT2 inhibitors for CKD patients
Clinical practice for SGLT2 inhibitors
4. OUTLINE
Mechanism of SGLT2 inhibitor with renal protection
Landmark trial of Dapagliflozin on renal outcomes
Updated guideline on SGLT2 inhibitors for CKD patients
Clinical practice for SGLT2 inhibitors
5. DEVELOPMENT OF SGLT2 INHIBITORS
Phlorizin
“Phlorizin” isolated from apple bark in 1835
SGLT1 and SGLT2 inhibition but poor oral absorption
Resurgence of interest in 1990s led to new drugs
Development of the “Gliflozins”
Dapagliflozin is the first molecule in SGLT2i class
approved in T2D
6. Cowie, M.R., Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 17, 761–772 (2020).
RENAL GLUCOSE
REABSORPTION
> 90%
< 10%
Glucose
reabsorption
160-180 g/day
Glucose
Filtration
160-180 g/day
No glucose
excretion
Normal
9. RENAL HEMODYNAMIC EFFECTS WITH SGLT2 INHIBITOR
Chilton RJ. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. Diabetes Obes Metab. 2020;22(1):16-29.
10. RENAL-PROTECTIVE PATHWAYS WITH SGLT2 INHIBITORS
Reduce inflammation
Restoration of TGF
Enhanced ketogenesis
Weight loss
Decrease BP
Increase Hct
Reduce arterial stiffness
Giorgino et al. Cardiovasc Diabetol (2020) 19:196
Decrease plasma volume
11. DAPAGLIFLOZIN
HbA1c
~ 0.5% to 1% decrease from
baseline
2/3 of the weight loss from
reductions in fat, both abdominal VAT
and SAT volumes
Weight
~1.5 to 3 kg weight loss from
baseline
SBP
Cardiovascular effect
Renoprotective effect
5.1 mm Hg reduction from
baseline at 24 weeks
eGFR
UACR
Remains stable out to 4 years
Improves albuminuria (-33%) on top
of ACEi/ARB at 12 weeks
Yu kurata, et al. Expert Review of Endocrinology & Metabolism, 17:4. 275-291
SGLT-
Inhibitor
Selectivity
(SGLT2 vs
STLT1)
Dosage (mg) Half-life
Dapagliflozin >1400-times 5-10 mg 13 h
Canagliflozin 250-times 100-300 mg 11-13 h
Empagliflozin >2500-times 10-25 mg 13 h
Ertugliflozin 2000-times 5-15 mg 16.6 h Hct Increase 2-3% from baseline
12. PHARMACOKINETICS OF SGLT2 INHIBITORS
Dapagliflozin Empagliflozin Canagliflozin Ertugliflozin
Absorption (T max) 2 h 1.5 h 1-2 h 1 h
Bioavailability 78% 78% 65% 100%
Fraction bound to
protein
91% 86% 99% 93.6%
Volume of distribution 118 L 73.8 L 83.5 L 86 L
Half life 12.9 h 12.4 h 13.1 h 17 h
SGLT2 inhibition IC50 1.2 nM 3.1 nM 2.7 nM 0.9 nM
SGLT1 inhibition IC50 1400 nM 8300 nM 710 nM 1960 nM
Metabolism Glucuronidation Glucuronidation Glucuronidation Glucuronidation
Elimination route 21% feces
75% urine
41% feces
54% urine
52% feces
33% urine
41% feces
50% urine
Adapted from Papakitsou et al. Clinical Pharmacology; Advances and Applications 2019:11
13. OUTLINE
Mechanism of SGLT2 inhibitor with renal protection
Landmark trial of Dapagliflozin on renal outcomes
Updated guideline on SGLT2 inhibitors for CKD patients
Clinical practice for SGLT2 inhibitors
15. DECLARE-TIMI 58: Broad CV risk population & 2 clinically
relevant and important CV primary endpoints in type 2 diabetes
Placebo
Dapagliflozin (10 mg per day)
1:1
Double-blind
T2D, ≥40 years plus:
▪ Multiple (≥2) risk factors OR
▪ Established CV disease
N=17,160
Primary
Endpoints
CV death, MI, stroke (MACE)
Hospitalization for heart failure or CV
death
Composite endpoint of
Composite endpoint of
Secondary Endpoints
• Renal composite endpoint
• All-cause mortality
Baseline Characteristics
Dapa
(N=8,582)
Placebo
(N=8,578)
HbA1C, %, mean (SD) 8.3 (1.2) 8.3 (1.2)
eGFR, mean (SD) 85.4 (15.8) 85.1 (16.0)
Multiple risk factors, n (%) 10,186 (59.4%)
Est CV disease, n (%) 6,974 (40.6%)
median follow-up of 4.2 years
Primary outcomes: Dapagliflozin did not result in a lower
rate of MACE but did result in a lower rate of
cardiovascular death or hospitalization for heart failure
16. Time since randomization (years)
5389
7409
7932
8056
8200
8326
8422
8508
8578
Placebo
5472
7534
8009
8136
8248
8347
8436
8533
8582
DAPA 10 mg
No. at Risk
0.06
0.05
0.04
0.03
0.02
0.01
0
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
Cumulative
Probability
of
Event
Placebo (5.6%)
DAPA 10 mg (4.3%)
HR 95% CI p-value*
0.76 (0.67, 0.87) <0.0001
Dapagliflozin is shown to reduce
progression to Nephropathy in ALL
T2D patients (with multiple CV risk
factors or established CV disease)
vs placebo
24%
DECLARE-TIMI 58: Secondary Renal Composite Outcome:
Decrease eGFR ≥40%, ESRD or Renal or CV Death
17. Change in eGFR over Time Improvement of Albuminuria
Deterioration of Albuminuria
DECLARE-TIMI 58: Renal outcomes
20. DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE
4304 patients
• Composite of sustained
≥50% eGFR decline, ESKD, or renal death
• Composite of CV death or hHF
• All-cause mortality
Secondary Outcomes
Dapagliflozin 10 mg
+ standard of care
Placebo
+ standard of care
1:1
Double-blind
End
Points
Composite of sustained ≥50% eGFR decline,
ESKD, renal or CV death
Primary Outcome
Median follow-up 2.4 years
N Engl J Med 2020; 383:1436-1446
21. DIABETES STATUS AND INVESTIGATOR-REPORTED CAUSE OF
KIDNEY DISEASE AT BASELINE
Diabetes Status
67.5%
32.5%
With type 2 diabetes
Without type 2 diabetes
Diabetic nephropathy
Glomerulonephritis
Ischemic / hypertensive nephropathy
Other / unknown causes
16.0%
16.1%
Investigator-reported Cause of Kidney Disease
58.3%
9.6%
N Engl J Med 2020; 383:1436-1446
22. PRIMARY COMPOSITE OUTCOMES
2152 2001 1955 1898 1841 1701 1288 831 309
2152 1993 1936 1858 1791 1664 1232 774 270
DAPA 10 mg
Placebo
DAPA 10 mg
197 events
Placebo
312 events
0
4
8
12
16
20
24
0 4 8 12 16 20 24 28 32
Months from Randomization
Cumulative
Incidence
%
N at Risk NNT=19
39%
RRR
ESKD defined as the need for maintenance dialysis (peritoneal or hemodialysis) for at least 28 days and renal transplantation or sustained eGFR <15mL/min/1.73m2 for at least 28 days
DAPA
9.2%
Placebo
14.5%
HR (95% CI)
0.61 (0.51-0.72)
p-value
0.000000018
N Engl J Med 2020; 383:1436-1446
23. Number of Events
HR (95% CI)
DAPA 10 mg
(N=2152)
Placebo
(N=2152)
HR 95% CI p-value
Primary Composite Outcome
Composite of ≥50% eGFR Decline, ESKD,
or Renal or CV Death
197 312 0.61 (0.51, 0.72) 0.000000028
Components of the Primary Composite Outcome
≥50% eGFR Decline 112 201 0.53 (0.42, 0.67) <0.0001
ESKD 109 161 0.64 (0.50, 0.82) 0.0004
eGFR <15mL/min/1.73m2 84 120 0.67 (0.51, 0.88) 0.0045
Chronic Dialysis 68 99 0.66 (0.48, 0.90) 0.0080
Transplantation 3 8 NC
Renal Death 2 6 NC
CV Death 65 80 0.81 (0.58, 1.12) 0.2029
0.30 0.60 1.00 1.25
DAPA 10 mg Better Placebo Better
All Individual Components Contributed to the Significant
Primary Outcome Treatment Effect
N Engl J Med 2020; 383:1436-1446
24. PRIMARY OUTCOME TREATMENT EFFECT
Number of Events
HR (95% CI)
DAPA 10 mg
(N=2152)
Placebo
(N=2152)
HR 95% CI
p-value
Interaction
Composite of ≥50% eGFR Decline, ESKD, or Renal or CV Death
All Patients 197 312 0.61 (0.51, 0.72)
T2D at Baseline 0.24
Yes 152 229 0.64 (0.52, 0.79)
No 45 83 0.50 (0.35, 0.72)
UACR (mg/g) at Baseline 0.52
≤1000 44 84 0.54 (0.37, 0.77)
>1000 153 228 0.62 (0.50, 0.76)
eGFR (mL/min/1.73m2) at Baseline 0.22
<45 152 217 0.63 (0.51, 0.78)
≥45 45 95 0.49 (0.34, 0.69)
0.13 0.50 1.00 1.25
DAPA 10 mg Better Placebo Better
Treatment Benefit Was Consistent Across Key Pre-Specified Subgroups
N Engl J Med 2020; 383:1436-1446
25. CV DEATH OR HOSPITALIZATION FOR HEART FAILURE
1. Heerspink HJL et al. N Engl J Med. 2020; 383:1436-1446; 2. Heerspink HJL. Presented at: ESC Congress – The Digital Experience; August 29 – September 1, 2020.
DAPA 10 mg
100 events
Placebo
138 events
2152 2035 2021 2003 1975 1895 1502 1003 384
2152 2023 1989 1957 1927 1853 1451 976 360
DAPA 10 mg
Placebo
0
2
4
6
8
10
0 4 8 12 16 20 24 28 32
Months from Randomization
Cumulative
Incidence
%
N at Risk
29%
RRR
Secondary outcomes
26. ALL-CAUSE MORTALITY
Secondary outcomes
Heerspink HJL. Presented at: ESC Congress – The Digital Experience; August 29 - September 1, 2020. 2. Heerspink HJL et al. Nephrol Dial Transplant. 2020;35:274–282.
2152 2039 2029 2017 1998 1925 1531 1028 398
DAPA 10 mg
DAPA 10 mg
101 events
Placebo
146 events
0
2
4
6
8
10
12
0 4 8 12 16 20 24 28 32
Months from Randomization
Cumulative
Incidence
%
N at Risk
2152 2035 2018 1993 1972 1902 1502 1009 379
Placebo
31%
RRR
27. CHANGE IN ALBUMINURIA IN THE OVERALL POPULATION
Mean reduction in UACR dapagliflozin vs. placebo:
29.3% (95% CI 25.2, 33.1); p<0.001
Dapagliflozin 2152 2085 2047 2048 1943 1884 1843 1778 1631 1172 692 233
Placebo 2152 2090 2054 2033 1909 1854 1818 1748 1581 1135 640 229
Median (IQR) baseline UACR, mg/g
Dapagliflozin: 965 (472–1903)
Placebo: 934 (482–1868)
Dapagliflozin 10 mg
42.9% reduction
Placebo
19.2% reduction
0
-60
-40
-20
0 4 8 12 16 20 24 28 32
Time, months
Adjusted
Mean
Change
in
UACR,
%
(95%
CI)
2 36
28. CHANGE IN ALBUMINURIA BY T2D STATUS
Patients with T2D
35.1% mean reduction in UACR (dapagliflozin vs. placebo)
(95% CI 30.6, 39.4; p<0.001)
Patients without T2D
14.8% mean reduction in UACR (dapagliflozin vs. placebo)
(95% CI 5.9, 22.9; p=0.001)
1455
1451
1411
1415
1387
1383
1398
1368
1339
1297
1288
1258
1262
1237
1206
1182
1127
1088
826
791
482
446
159
158
Dapagliflozin
Placebo
697
701
674
675
660
671
650
665
604
612
596
596
581
581
572
566
504
493
346
344
210
194
74
71
Dapagliflozin
Placebo
Adjusted
Mean
Change
in
UACR,
%
(95%
CI)
0
60
-40
-20
0 4 8 12 16 20 24 28 32
Time, months
2 36
Dapagliflozin
-46.6%
Placebo
-17.7%
Adjusted
Mean
Change
in
UACR,
%
(95%
CI)
0
60
-40
-20
0 4 8 12 16 20 24 28 32
Time, months
2 36
Dapagliflozin
-33.9%
Placebo
-22.5%
Median (IQR) baseline UACR, mg/g
Dapagliflozin: 1025 (473–2111)
Placebo: 1005 (493–2017)
Median (IQR) baseline UACR, mg/g
Dapagliflozin: 870 (472–1554)
Placebo: 842 (459–1555)
29. CHANGE FROM BASELINE IN EGFR
0 4 8 12 16 20 24 28 32 36
-15
-10
-5
0
Months Since Randomization
Least-Squares
Mean
Change
in
eGFR
(mL/1.73m
2
)
DAPA
Mean BL eGFR: 43.2 mL/min/1.73m2
Placebo
Mean BL eGFR: 43.0 mL/min/1.73m2
No. of Patients
Dapagliflozin 2152 2031 2001 1896 1832 1785 1705 1482 978 496 157
Placebo 2152 2029 1981 1866 1795 1753 1672 1443 935 447 157
Heerspink HJL. Presented at: ESC Congress – The Digital Experience; August 29 - September 1, 2020. 2. Heerspink HJL et al. Nephrol Dial Transplant. 2020;35:274–282.
During first 2 weeks
Greater reduction in eGFR in DAPA
(-3.97±0.15 vs -0.82±0.15 mL/min/1.73m2)
From baseline to 30 months
Small reduction in eGFR in DAPA
(-2.86±0.11 vs -3.79±0.11 mL/min/1.73m2)
30.
31. SAFETY OUTCOMES
Safety Outcomesa, n (%)
Dapagliflozin 10 mg
(N=2149)
Placebo
(N=2149)
p-value
Discontinuation of study drug 274 (12.7) 309 (14.4) NA
Discontinuation due to adverse event 118 (5.5) 123 (5.7) 0.79
Any serious adverse event 633 (29.5) 729 (33.9) 0.002
Adverse events of interest
Amputationb
Any definite or probable diabetic ketoacidosis
Fracturec
Renal-related adverse event
Major hypoglycemiad
Volume depletion
Serious adverse events of volume depletion
35 (1.6)
0
85 (4.0)
155 (7.2)
14 (0.7)
127 (5.9)
22 (1.0)
39 (1.8)
2 (0.1)
69 (3.2)
188 (8.7)
28 (1.3)
90 (4.2)
18 (0.8)
0.73
0.50
0.22
0.07
0.04
0.01
NA
Fournier’s Gangrene 0 1(<0.1) NA
aSafety outcomes reported in participants on and off treatment; bSurgical or spontaneous/non-surgical amputation, excluding amputation due to trauma;
cBased on pre-defined list of preferred terms; dAdverse events with the following criteria confirmed by the investigator: i) symptoms of severe impairment in consciousness or behavior,
ii) need of external assistance, iii) intervention to treat hypoglycemia, iv) prompt recovery of acute symptoms following the intervention.
N Engl J Med 2020; 383:1436-1446
32. The Largest SGLT2i Development ProgramWorldwide
The FIRST treatment for patients with CKD, with and without T2D, to
improve cardiorenal outcomes and reduce mortality
39% RRR
in a composite of sustained ≥50% eGFR decline, ESKD, renal, or
CV death
HR, 0.61 (0.51-0.72); p<0.000000028
44% RRR
in composite outcome of sustained
≥50% eGFR decline, ESKD, or renal death
HR, 0.56 (0.45-0.68); p=0.000000018
29% RRR
in CV death or hHF
HR, 0.71 (0.55-0.92); p=0.0089
31% RRR
in all-cause mortality
HR, 0.69 (0.53-0.88); p=0.0035
Safety
Dapagliflozin was well tolerated, keeping with
its established safety profile
Adverse events rarely led to discontinuation of treatment
Very few events of major hypoglycemia or DKA
Trial stopped early due to overwhelming efficacy
• Results consistent in patients with and without T2D
• First renal outcomes study to show robust benefit on all-cause mortality
• HHF/CV benefit in CKD patients that is consistent with DAPA-HF
• With DECLARE demonstrates the ability to prevent and treat cardiorenal complications across the
spectrum of diabetic kidney disease severity
DAPA-CKD Overview
1:1
double-blind
Inclusion Criteria: ≥18 years, eGFR 25 to 75 mL/min/1.73m2
UACR 200–5000 mg/g, stable maximum tolerated dose of ACEi or ARB for
≥4 weeks (if not contraindicated)
DAPA 10 mg
n=2152
Placebo
n=2152
N=4304
32%
No T2D
68%
T2D
Placebo
Dapagliflozin
197 Events
312 Events
NNT=19
36% RRR in
patients with T2D
HR, 0.64 (0.52-0.79)
50% RRR in
patients without T2D
HR, 0.50 (0.35-0.72)
33. RENAL OUTCOMES IN DAPAGLIFLOZIN
a Because the trial met only one of its dual primary composite outcomes for superiority (CV death or hospital admission for heart failure), all other analyses of additional outcomes should
be considered hypothesis generating only.
ASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; ESKD = end-stage kidney disease; HF = heart
failure; HFrEF = heart failure with reduced ejection fraction; hHF = hospitalization for heart failure; T2D = type 2 diabetes.
1. Wiviott SD. et al. N Engl J Med. 2019;380:347-357. 2. McMurray JJV et al. N Engl J Med. 2019;381:1995-2008. 3. Heerspink HJL. Presented at: ESC Congress – The Digital Experience;
August 29 - September 1, 2020; 4. Heerspink HJL et al. Online ahead of print. N Engl J Med. 2020.
Patient
Population
Glycemic Status With T2D With (45%) or Without (55%) T2D With (68%) or Without (32%) T2D
Mean eGFR 85.2 mL/min/1.73m2 66 mL/min/1.73m2 43 mL/min/1.73m2
Primary
Endpoint
• hHF or CV death
0.83 (0.73, 0.95) p=0.005
• CV death or worsening HF (hHF, or urgent
hHF visit)
0.74 (0.65, 0.85) p<0.001
• ≥50% eGFR Decline, ESKD, or Renal or CV
Death
0.61 (0.51-0.72) p=0.000000028
Key
Endpoint
• eGFR decrease ≥40% to <60, ESKD or renal
death
0.53 (0.43, 0.66) p<0.0001a
• ≥50% sustained decline in eGFR,
ESKD or renal death
0.71 (0.44, 1.16) p=0.17
• CV death or hHF
0.71 (0.55, 0.92) p=0.0089
ASCVD (~40%) or MRF (~60%)
eGFR ≥60 mL/min/1.73m2
HFrEF
eGFR ≥30 mL/min/1.73m2
CKD
eGFR ≥25 to ≤75 mL/min/1.73m2
N = 17,1601
N = 47442 N = 43043,4
CV
Renal
34. OUTLINE
Mechanism of SGLT2 inhibitor with renal protection
Landmark trial of Dapagliflozin on renal outcomes
Updated guideline on SGLT2 inhibitors for CKD patients
Clinical practice for SGLT2 inhibitors
35. Ian H. de Boer, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022
Published Oct 2022
38. KDIGO guideline on diabetes in CKD 2022
Recommend an eGFR > 20 ml/min
per 1.73 m2 with an SGLT2i
39. KDIGO 2022 GUIDELINES
Recommendation 1.3.1: We recommend treating patients with T2D, CKD, and an eGFR > 20
ml/min per 1.73 m2 with an SGLT2i (1A).
• The recommendation for SGLT2i is for kidney and cardiovascular protection and has been shown to have
safety and benefit in CKD with or without T2D
• Withhold SGLT2i during times of prolonged fasting, surgery, or critical medical illness (when patients may be
at greater risk for ketosis).
• If a patient is at risk for hypovolemia, consider decreasing thiazide or loop diuretic dosages
• Advise patients about symptoms of volume depletion and low blood pressure, and follow up on volume
status after drug initiation.
• A reversible decrease in the eGFR with commencement of SGLT2i treatment may occur and is generally NOT
an indication to discontinue therapy.
• Once an SGLT2i is initiated, it is reasonable to continue an SGLT2i even if the eGFR falls below 20 ml/min per
1.73 m2 , unless it is not tolerated or kidney replacement therapy is initiate.
Practical Points
KDIGO guideline on diabetes in CKD 2022
40. Ian H. de Boer, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022
41. ADA AND KDIGO 2022 RECOMMENDATION
Ian H. de Boer, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022
42. OUTLINE
Mechanism of SGLT2 inhibitor with renal protection
Landmark trial of Dapagliflozin on renal outcomes
Updated guideline on SGLT2 inhibitors for CKD patients
Clinical practice for SGLT2 inhibitors
44. PERIPROCEDURAL MANAGEMENT
• Inform patients about risk of DKA associated with procedure.
• Procedure required admission or colonoscopy → Stop SGLT2i at least 3 days pre-
procedure (2 days prior to surgery and the day of surgery)
• Day-stay procedure → Stop SGLT2i at the day of procedure. However, fasting before
and after the procedure should be minimized
• Measure blood glucose and blood ketone levels.
• If patients is clinically well and ketone < 1 mmol/L → Proceed to surgery
• Consider hourly blood glucose and blood ketone testing during procedure and 2
hourly following procedure until eating and drinking normally.
• Restart SGLT2i only when the patient is eating and drinking normally or close to
discharge to hospital
• Patient who have day surgery/procedure should only recommence SGLT2i if on full oral
intake. Consider delaying recommencement for a further 24 h
Pre-procedure
On admission
Post-procedure
Australian Diabetes Society. Periprocedural diabetic ketoacidosis with SGLT2 inhibitors use. Jan 2020
45. TAKE HOME MESSAGE - MY CLINICAL PRACTICE
Stable hemodynamic and
renal function
Pre-initiation eGFR
Pre-initiation albuminuria
Empagliflozin ≥ 200 mg/g
if eGFR 45-90
ml/min/1.73m2
Dapagliflozin 200-5000
mg/g
Canagliflozin 300-5000
mg/g
Patients with T2DM with at
high risk for CV disease,
already on metformin
• Below HbA1C target →
Switch non-metformin to
SGLT2i
• Above HbA1c target →
Start SGLT2i
Patients with both HFrEF and
HFpEF
Patients with CKD (eGFR > 20)
esp. albuminuria
Drugs
Empagliflozin (Jardiance®),
Dapagliflozin (Forxiga®),
Canagliflozin (Invokana®)
Starting dose
Consider combination
therapy to limit non-
adherence and pill burden
Anticipatory guidance
Decrease dose diuretic, anti-
hyperglycemic drugs
Patients counseling
Genital/ perineal hygiene
Orthostatic hypotension
Symptom of DKA
Avoid excessive alcohol
Multidisciplinary care team
Follow-up and Monitoring
• Self-assessment of renal function,
BW, BP, and symptoms
• Dose up-titrate guide by glycemic
control (Not HF and renal)
• Essure adherence to SGLT2
• Multidisciplinary care team
Discontinuation
• Withhold if prolonged fasting,
surgery, or critical medical illness
• Receiving RRT
DAPA 10 mg
DAPA ≥ 25
ml/min/1.73m2
Adapted from Orly Vardeny, et al. JACC, 2019